340 related articles for article (PubMed ID: 33074781)
1. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.
Conforti C; Dianzani C; Zalaudek I; Cicala M; Persichetti P; Giuffrida R; Morariu SH; Neagu N
J Dermatolog Treat; 2022 May; 33(3):1279-1286. PubMed ID: 33074781
[TBL] [Abstract][Full Text] [Related]
2. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.
Hwang JK; Ricardo JW; Lipner SR
Am J Clin Dermatol; 2023 Sep; 24(5):695-720. PubMed ID: 37209391
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
Wu J; Smogorzewski J
Dermatol Ther; 2021 May; 34(3):e14883. PubMed ID: 33594811
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.
Kaushik SB; Lebwohl MG
J Am Acad Dermatol; 2019 Jan; 80(1):27-40. PubMed ID: 30017705
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
8. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
11. Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.
Mikhaylov D; Hashim PW; Nektalova T; Goldenberg G
J Clin Aesthet Dermatol; 2019 Jun; 12(6):46-54. PubMed ID: 31360288
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
13. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
14. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections.
Kaushik SB; Lebwohl MG
J Am Acad Dermatol; 2019 Jan; 80(1):43-53. PubMed ID: 30017706
[TBL] [Abstract][Full Text] [Related]
17. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
[TBL] [Abstract][Full Text] [Related]
18. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
19. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
Xie W; Xiao S; Huang H; Zhang Z
Front Immunol; 2022; 13():847160. PubMed ID: 35300336
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]